Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca (AZN) and Daiichi Sankyo's datopotamab deruxtecan in first-line nonsquamous non-small cell lung cancer ...

On today's call, I would like to highlight some of our key achievements in 2025 and outline our planned strategic priorities ...

HOLON, Israel, March 9, 2020 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, reported today updated data from its ...

HOLON, Israel, July 19, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first ...

COM503 a potential first-in-class, high affinity anti- IL18 binding protein antibody frees endogenous IL-18 to inhibit cancer growth Compugen plans to file COM503 IND in 2024 "We are very excited to ...

Compugen (CGEN) came out with quarterly earnings of $0.6 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to a loss of $0.07 per share a year ago. These figures are ...

Compugen focuses on immunotherapies to treat cancer. The company has more than doubled its share price since last month. The clinical-stage biotech is not yet profitable. The stock closed on Wednesday ...

COM902 and COM701 will allow the Company to clinically evaluate the dual blockade of PVRIG and TIGIT inhibitory pathways in the DNAM axis HOLON, Israel, April 6, 2020 /PRNewswire/ -- Compugen Ltd.

HOLON, Israel, Feb. 17, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI ...

Compugen, a data-science-driven biotechnology company focused on target and biomarker discovery in IO, has developed proprietary predictive computational solutions to untangle this complexity, ...

Ambitious Israel-based biotech Compugen's (NASDAQ: CGEN) stock had one of the best days in its history Thursday. The shares rose 14% after the company revealed that a deep-pocketed strategic investor ...

HOLON, Israel, Feb. 12, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI ...